JP2012528796A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012528796A5 JP2012528796A5 JP2012513346A JP2012513346A JP2012528796A5 JP 2012528796 A5 JP2012528796 A5 JP 2012528796A5 JP 2012513346 A JP2012513346 A JP 2012513346A JP 2012513346 A JP2012513346 A JP 2012513346A JP 2012528796 A5 JP2012528796 A5 JP 2012528796A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- beta
- binding
- coronary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims description 70
- 239000008194 pharmaceutical composition Substances 0.000 claims description 47
- 230000007211 cardiovascular event Effects 0.000 claims description 41
- 230000000250 revascularization Effects 0.000 claims description 34
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 16
- 230000002093 peripheral effect Effects 0.000 claims description 15
- 239000013543 active substance Substances 0.000 claims description 14
- 208000010125 myocardial infarction Diseases 0.000 claims description 14
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 13
- 239000008280 blood Substances 0.000 claims description 13
- 210000004369 blood Anatomy 0.000 claims description 13
- 206010020772 Hypertension Diseases 0.000 claims description 12
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 12
- 208000006011 Stroke Diseases 0.000 claims description 12
- 208000020832 chronic kidney disease Diseases 0.000 claims description 12
- 208000029078 coronary artery disease Diseases 0.000 claims description 12
- 238000013146 percutaneous coronary intervention Methods 0.000 claims description 12
- 206010002383 Angina Pectoris Diseases 0.000 claims description 11
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 11
- 102100032752 C-reactive protein Human genes 0.000 claims description 11
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 10
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 9
- 206010019280 Heart failures Diseases 0.000 claims description 9
- 235000012000 cholesterol Nutrition 0.000 claims description 8
- 210000004351 coronary vessel Anatomy 0.000 claims description 8
- 208000037803 restenosis Diseases 0.000 claims description 8
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 6
- 201000001320 Atherosclerosis Diseases 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 6
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims description 6
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 6
- 206010027525 Microalbuminuria Diseases 0.000 claims description 6
- 208000008589 Obesity Diseases 0.000 claims description 6
- 102000003982 Parathyroid hormone Human genes 0.000 claims description 6
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 6
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 6
- 208000007536 Thrombosis Diseases 0.000 claims description 6
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 6
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 6
- 238000013172 carotid endarterectomy Methods 0.000 claims description 6
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 201000001421 hyperglycemia Diseases 0.000 claims description 6
- 238000002513 implantation Methods 0.000 claims description 6
- 230000004054 inflammatory process Effects 0.000 claims description 6
- 235000020824 obesity Nutrition 0.000 claims description 6
- 239000000199 parathyroid hormone Substances 0.000 claims description 6
- 229960001319 parathyroid hormone Drugs 0.000 claims description 6
- 238000007888 peripheral angioplasty Methods 0.000 claims description 6
- 239000011574 phosphorus Substances 0.000 claims description 6
- 229910052698 phosphorus Inorganic materials 0.000 claims description 6
- 230000000391 smoking effect Effects 0.000 claims description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 6
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 5
- 206010014486 Elevated triglycerides Diseases 0.000 claims description 5
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims description 5
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 5
- 208000032109 Transient ischaemic attack Diseases 0.000 claims description 5
- 230000001154 acute effect Effects 0.000 claims description 5
- 239000002220 antihypertensive agent Substances 0.000 claims description 5
- 230000009885 systemic effect Effects 0.000 claims description 5
- 201000010875 transient cerebral ischemia Diseases 0.000 claims description 5
- 208000010496 Heart Arrest Diseases 0.000 claims description 4
- 238000008214 LDL Cholesterol Methods 0.000 claims description 4
- 229940030600 antihypertensive agent Drugs 0.000 claims description 4
- 238000010494 dissociation reaction Methods 0.000 claims description 4
- 230000005593 dissociations Effects 0.000 claims description 4
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 4
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 4
- 230000001631 hypertensive effect Effects 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 102000008873 Angiotensin II receptor Human genes 0.000 claims description 3
- 108050000824 Angiotensin II receptor Proteins 0.000 claims description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 3
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 3
- 241000208011 Digitalis Species 0.000 claims description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 3
- 239000003529 anticholesteremic agent Substances 0.000 claims description 3
- 229940127226 anticholesterol agent Drugs 0.000 claims description 3
- 239000003146 anticoagulant agent Substances 0.000 claims description 3
- 229940127219 anticoagulant drug Drugs 0.000 claims description 3
- 239000000480 calcium channel blocker Substances 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 239000002934 diuretic Substances 0.000 claims description 3
- 239000003527 fibrinolytic agent Substances 0.000 claims description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 3
- 229960000103 thrombolytic agent Drugs 0.000 claims description 3
- 229940124549 vasodilator Drugs 0.000 claims description 3
- 239000003071 vasodilator agent Substances 0.000 claims description 3
- 102000019223 Interleukin-1 receptor Human genes 0.000 claims description 2
- 108050006617 Interleukin-1 receptor Proteins 0.000 claims description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 239000002876 beta blocker Substances 0.000 claims description 2
- 229940097320 beta blocking agent Drugs 0.000 claims description 2
- 230000036772 blood pressure Effects 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 230000003472 neutralizing effect Effects 0.000 claims description 2
- 229960003512 nicotinic acid Drugs 0.000 claims description 2
- 235000001968 nicotinic acid Nutrition 0.000 claims description 2
- 239000011664 nicotinic acid Substances 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims 2
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 229940127088 antihypertensive drug Drugs 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 210000001715 carotid artery Anatomy 0.000 claims 1
- 229940030606 diuretics Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 description 113
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 3
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000003087 receptor blocking agent Substances 0.000 description 2
- -1 statin Substances 0.000 description 2
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical group C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 229940097420 Diuretic Drugs 0.000 description 1
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 description 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- KPBZROQVTHLCDU-GOSISDBHSA-N clevidipine Chemical compound CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@H]1C1=CC=CC(Cl)=C1Cl KPBZROQVTHLCDU-GOSISDBHSA-N 0.000 description 1
- 229960003597 clevidipine Drugs 0.000 description 1
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 description 1
- 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229960001632 labetalol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 229940083618 sodium nitroprusside Drugs 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18267909P | 2009-05-29 | 2009-05-29 | |
| US61/182,679 | 2009-05-29 | ||
| US25257109P | 2009-10-16 | 2009-10-16 | |
| US61/252,571 | 2009-10-16 | ||
| US31300110P | 2010-03-11 | 2010-03-11 | |
| US61/313,001 | 2010-03-11 | ||
| PCT/US2010/036761 WO2010138939A1 (en) | 2009-05-29 | 2010-05-28 | CARDIOVASCULAR RELATED USES OF IL-1ß ANTIBODIES AND BINDING FRAGMENTS THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015000602A Division JP2015120704A (ja) | 2009-05-29 | 2015-01-06 | ＩＬ−１β抗体およびその結合断片の心血管関連の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012528796A JP2012528796A (ja) | 2012-11-15 |
| JP2012528796A5 true JP2012528796A5 (cg-RX-API-DMAC7.html) | 2013-07-18 |
| JP5763625B2 JP5763625B2 (ja) | 2015-08-12 |
Family
ID=43223130
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012513346A Active JP5763625B2 (ja) | 2009-05-29 | 2010-05-28 | ＩＬ−１β抗体およびその結合断片の心血管関連の使用 |
| JP2015000602A Pending JP2015120704A (ja) | 2009-05-29 | 2015-01-06 | ＩＬ−１β抗体およびその結合断片の心血管関連の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015000602A Pending JP2015120704A (ja) | 2009-05-29 | 2015-01-06 | ＩＬ−１β抗体およびその結合断片の心血管関連の使用 |
Country Status (15)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150094344A1 (en) * | 2011-04-01 | 2015-04-02 | The Medicines Company | Short-acting dihydropyridines (clevidipine) for use in reducing stroke damage |
| AR088083A1 (es) * | 2011-09-30 | 2014-05-07 | Novartis Ag | USO DE ANTICUERPOS DE UNION A IL-1b |
| ES2534782T3 (es) * | 2012-02-02 | 2015-04-28 | Baylor College Of Medicine | Sistema biológico de administración y expresión basado en adenovirus para uso en el tratamiento de la osteoartritis |
| CN103588878A (zh) * | 2012-08-15 | 2014-02-19 | 江苏泰康生物医药有限公司 | 一种人源化抗人白细胞介素1 β单克隆抗体及其制备与应用 |
| EP3524621A1 (en) * | 2012-10-04 | 2019-08-14 | XBiotech, Inc | Treating vascular disease and complications thereof |
| CA2891556A1 (en) * | 2012-11-16 | 2014-05-22 | Novartis Ag | Use of il-1 beta binding antibodies for treating peripheral arterial disease |
| US10000557B2 (en) * | 2012-12-19 | 2018-06-19 | Dnae Group Holdings Limited | Methods for raising antibodies |
| CN103059136A (zh) * | 2012-12-24 | 2013-04-24 | 浙江大学 | 抗中华鳖IL-1β多克隆抗体的制备及在检测中的应用 |
| KR102337954B1 (ko) * | 2018-08-16 | 2021-12-10 | 차의과학대학교 산학협력단 | 뇌졸중 치료용 조성물 및 이를 스크리닝하는 방법 |
| JP2022531328A (ja) * | 2019-05-03 | 2022-07-06 | ユニバーシティ・オブ・チューリッヒ | 脳虚血再灌流傷害の治療 |
| US20220275079A1 (en) * | 2020-11-20 | 2022-09-01 | The General Hospital Corporation | Clonal Hematopoiesis and Risk of Chronic Liver Disease |
| GB202400340D0 (en) | 2024-01-10 | 2024-02-21 | Wotherspoon Hugh Robert | IL-1B binding antibody |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7820383B2 (en) * | 1997-03-10 | 2010-10-26 | Interleukin Genetics, Inc. | Method for diagnosing myocardial infarction |
| AR016551A1 (es) * | 1997-07-30 | 2001-07-25 | Smithkline Beecham Corp | Derivados de 2-oxindol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos |
| US6635249B1 (en) * | 1999-04-23 | 2003-10-21 | Cenes Pharmaceuticals, Inc. | Methods for treating congestive heart failure |
| US7860583B2 (en) * | 2004-08-25 | 2010-12-28 | Carefusion 303, Inc. | System and method for dynamically adjusting patient therapy |
| EP1379197A4 (en) * | 2001-03-23 | 2009-06-03 | Durect Corp | DISPOSAL OF MEDICINAL PRODUCTS OF DELAYED RELEASE DEVICES IMPLANTED IN MYOKARD TISSUE OR PER ICARDROOM |
| US20040106954A1 (en) * | 2002-11-15 | 2004-06-03 | Whitehurst Todd K. | Treatment of congestive heart failure |
| WO2004100987A2 (en) | 2003-05-06 | 2004-11-25 | Regeneron Pharmaceuticals, Inc. | Methods of using il-1 antagonists to treat neointimal hyperplasia |
| EP1851245B1 (en) * | 2005-01-26 | 2012-10-10 | Amgen Fremont Inc. | Antibodies against interleukin-1 beta |
| US20060171948A1 (en) * | 2005-02-02 | 2006-08-03 | Weinstein Steven P | Methods of using IL-1 antagonists to reduce C-reactive protein |
| WO2006084145A2 (en) * | 2005-02-02 | 2006-08-10 | Regeneron Pharmaceuticals, Inc. | Methods of using il-1 antagonists to reduce c-reactive protein |
| US9296816B2 (en) | 2005-04-15 | 2016-03-29 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| ES2335232T3 (es) * | 2005-06-21 | 2010-03-23 | Xoma Technology Ltd. | Anticuerpos y fragmentos de los mismos que se unen a la il-1 beta. |
| WO2007042524A2 (en) | 2005-10-14 | 2007-04-19 | Novo Nordisk A/S | Treating diabetes using inhibitors of il-1 |
| JP4524275B2 (ja) * | 2006-09-01 | 2010-08-11 | 日本ポリプロ株式会社 | ビニル基および極性基含有プロピレン系共重合体及びそれを用いる重合体の製造方法。 |
| JP5645409B2 (ja) * | 2006-12-20 | 2014-12-24 | ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー | ＩＬ−１β関連疾患の治療方法 |
-
2010
- 2010-05-28 CN CN201710537454.6A patent/CN107243077A/zh active Pending
- 2010-05-28 CN CN2010800330317A patent/CN102573893A/zh active Pending
- 2010-05-28 JP JP2012513346A patent/JP5763625B2/ja active Active
- 2010-05-28 BR BRPI1011228A patent/BRPI1011228A2/pt not_active IP Right Cessation
- 2010-05-28 MX MX2011012666A patent/MX2011012666A/es active IP Right Grant
- 2010-05-28 KR KR1020117031198A patent/KR20120061041A/ko not_active Withdrawn
- 2010-05-28 NZ NZ597024A patent/NZ597024A/en not_active IP Right Cessation
- 2010-05-28 EP EP10781360A patent/EP2435073A4/en not_active Withdrawn
- 2010-05-28 SG SG10201500180RA patent/SG10201500180RA/en unknown
- 2010-05-28 SG SG2011087723A patent/SG176265A1/en unknown
- 2010-05-28 WO PCT/US2010/036761 patent/WO2010138939A1/en not_active Ceased
- 2010-05-28 EA EA201101643A patent/EA201101643A1/ru unknown
- 2010-05-28 CA CA2763161A patent/CA2763161A1/en not_active Abandoned
- 2010-05-28 AU AU2010253924A patent/AU2010253924B2/en not_active Ceased
- 2010-05-28 SG SG2014014534A patent/SG2014014534A/en unknown
- 2010-05-28 US US12/790,738 patent/US20100316651A1/en not_active Abandoned
-
2011
- 2011-11-28 IL IL216660A patent/IL216660A0/en unknown
-
2015
- 2015-01-06 JP JP2015000602A patent/JP2015120704A/ja active Pending
-
2017
- 2017-07-11 US US15/647,203 patent/US10611832B2/en active Active
-
2018
- 2018-04-09 HK HK18104608.6A patent/HK1245111A1/zh unknown
-
2020
- 2020-02-24 US US16/799,707 patent/US20210009679A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012528796A5 (cg-RX-API-DMAC7.html) | ||
| JP7426940B2 (ja) | 心血管リスクを低減するためのｐｃｓｋ９阻害剤の使用 | |
| JP2017509624A5 (cg-RX-API-DMAC7.html) | ||
| JP2024129139A (ja) | ベンラリツマブを使用して喘息の増悪率を低減する方法 | |
| JP2014516953A5 (cg-RX-API-DMAC7.html) | ||
| Tziomalos et al. | Fenofibrate: a novel formulation (Triglide™) in the treatment of lipid disorders: a review | |
| JP2023071715A (ja) | アテローム動脈硬化性心血管疾患を含むアテローム性動脈硬化症の併用療法 | |
| Wan et al. | Drug discovery for coronary artery disease | |
| CN119564834A (zh) | 度拉糖肽的治疗用途 | |
| Polonsky et al. | Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy | |
| JP7781786B2 (ja) | アテローム性動脈硬化性心血管疾患を治療するための医薬化合物 | |
| Bach | Adjunctive pharmacologic therapies in acute myocardial infarction | |
| Robson | Iron supplementation reduces re-hospitalization for heart failure | |
| Jonas Häner et al. | Evolocumab for Early Reduction of LDL-Cholesterol Levels in Patients with Acute Coronary Syndromes (EVOPACS) | |
| EP4122493A1 (en) | Method for treating cholesterol-related diseases | |
| EA049586B1 (ru) | Средства комбинированной терапии атеросклероза, включая атеросклеротическое сердечно-сосудистое заболевание | |
| Tonkin et al. | Lipid-lowering agents: Andrew M. Tonkin and Omar Farouque Overview of clinical trials | |
| Furst et al. | Systemic Sclerosis: Current and future prospects in management | |
| Tjokroprawiro | THE 22 PLEIOTROPIC PROPERTIES OF STATIN AND CARDIOVASCULAR DISEASES The Roles of Atorvastatin with Its PPECCAT-GOMMESAAB Effects. | |
| NZ757487B2 (en) | Methods for treating hepcidin-mediated disorders | |
| Fuchs | Itsik Ben-Dor1, 2, Ran Kornowski1, 2, & | |
| NZ794398A (en) | Combined Therapies For Atherosclerosis, Including Atherosclerotic Cardiovascular Disease | |
| TH2001001181A (th) | วิธีการสำหรับการบำบัดโรคที่เกี่ยวข้องกับ-tnf | |
| NZ757487A (en) | Methods for treating hepcidin-mediated disorders |